Supportive Care Articles

Experts Discuss Ways to Remove Barriers to Optimal Management of CINV
Despite the widespread availability of antiemetic regimens, between 30% and 50% of patients receiving chemotherapy experience treatment-related nausea and/or vomiting.
The FDA has approved intravenous rolapitant for use in combination with other antiemetic agents to treat delayed chemotherapy-induced nausea and vomiting in adults.
FDA Issues Complete Response Letter for Pegfilgrastim Biosimilar
Biocon has announced that the FDA has issued a complete response letter for Mylan’s biologics License Application for MYL-1401H, a proposed biosimilar for Amgen’s pegfilgrastim (Neulasta).
FDA Approves Ibrutinib for GVHD
The FDA has approved ibrutinib for the treatment of adult patients with chronic graft versus host disease following the failure of 1 or more lines of systemic therapy. The BTK inhibitor is now the first FDA-approved therapy for the treatment of cGVHD.
Expert Stresses True Definition of Palliative Care for Patients With Lung Cancer
Rachel Dibble, NP, discusses the importance of palliative care at the start of diagnosis for patients with non-small cell lung cancer and explained its differences from end-of-life care.
FDA Expands Cooling Cap Alopecia Approval to Cover Solid Tumors
The FDA has expanded the indication for the DigniCap Cooling System to be used for alopecia reduction across all solid tumors.
Informed Patients Are More Likely to Choose Palliative Care
Research from Tulane University provides a strong case that, across demographic and clinical populations, informed patients are less wary of palliative care and more inclined to take advantage of the favorable effects that palliative care services can offer for patient-centered outcomes.
Advances in treatment and supportive care have resulted in substantial improvements in cancer survival and a growing number of cancer survivors in the United States.
The rate of severe long-term side effects caused by treatments for childhood cancers is dropping over time, according to findings from a retrospective analysis of 23,600 survivors enrolled in the Childhood Cancer Survivor Study.
European Commission Approves Oral Rolapitant for CINV
The European Commission has approved oral rolapitant tablets for the treatment of delayed chemotherapy-induced nausea and vomiting in adults.
Publication Bottom Border
Border Publication